168 related articles for article (PubMed ID: 36809443)
1. In vitro effects of gamma-secretase inhibition in HPV-positive and HPV-negative head and neck squamous cell carcinoma.
Varatanovic S; Maier T; Al-Gboore S; Stoiber S; Kandathil SA; Quint C; Brennus C; Heiduschka G; Kadletz-Wanke L; Brkic FF
Invest New Drugs; 2023 Apr; 41(2):193-201. PubMed ID: 36809443
[TBL] [Abstract][Full Text] [Related]
2. In vitro antineoplastic effects of MK0752 in HPV-positive head and neck squamous cell carcinoma.
Varatanovic S; Stoiber S; Haas M; Lein A; Kadletz-Wanke L; Brkic FF
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14691-14699. PubMed ID: 37587308
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
Zuo N; Ma L; Liu T; Hu W; Luo Y; Meng H; Ren Q; Deng Y; Wei L; Liu Q
Oral Oncol; 2023 May; 140():106367. PubMed ID: 36996606
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of beta-catenin shows therapeutic potential in head and neck squamous cell carcinoma in vitro.
Maier T; Stoiber S; Gurnhofer E; Haas M; Kenner L; Heiduschka G; Kadletz-Wanke L; Brkic FF
Eur Arch Otorhinolaryngol; 2023 Jan; 280(1):399-408. PubMed ID: 36001136
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Aderhold C; Umbreit C; Faber A; Sauter A; Sommer JU; Birk R; Erben P; Hofheinz RD; Stern-Straeter J; Hörmann K; Schultz JD
Anticancer Res; 2013 May; 33(5):1951-61. PubMed ID: 23645743
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
[TBL] [Abstract][Full Text] [Related]
7. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.
Gu Z; Shi C; Li J; Han Y; Sun B; Zhang W; Wu J; Zhou G; Ye W; Li J; Zhang Z; Zhou R
BMC Med; 2022 May; 20(1):175. PubMed ID: 35546399
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation.
Liu C; Sadat SH; Ebisumoto K; Sakai A; Panuganti BA; Ren S; Goto Y; Haft S; Fukusumi T; Ando M; Saito Y; Guo T; Tamayo P; Yeerna H; Kim W; Hubbard J; Sharabi AB; Gutkind JS; Califano JA
Clin Cancer Res; 2020 Jun; 26(11):2693-2703. PubMed ID: 31932491
[TBL] [Abstract][Full Text] [Related]
9. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
[TBL] [Abstract][Full Text] [Related]
10. Wild-type p53 reactivation by small-molecule Minnelide™ in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma.
Caicedo-Granados E; Lin R; Fujisawa C; Yueh B; Sangwan V; Saluja A
Oral Oncol; 2014 Dec; 50(12):1149-56. PubMed ID: 25311433
[TBL] [Abstract][Full Text] [Related]
11. Differential anticancer activities of arsenic trioxide on head and neck cancer cells with different human papillomavirus status.
Du S; Liu K; Gao P; Li Z; Zheng J
Life Sci; 2018 Nov; 212():182-193. PubMed ID: 30243648
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line.
Harris M; Wang XG; Jiang Z; Goldberg GL; Casadevall A; Dadachova E
Head Neck Oncol; 2011 Feb; 3(1):9. PubMed ID: 21314983
[TBL] [Abstract][Full Text] [Related]
13. Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma.
Yang Z; Liao J; Schumaker L; Carter-Cooper B; Lapidus RG; Fan X; Gaykalova DA; Mehra R; Cullen KJ; Dan H
Oral Oncol; 2022 Aug; 131():105939. PubMed ID: 35667295
[TBL] [Abstract][Full Text] [Related]
14. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
Coppock JD; Wieking BG; Molinolo AA; Gutkind JS; Miskimins WK; Lee JH
Neoplasia; 2013 Jun; 15(6):620-30. PubMed ID: 23730210
[TBL] [Abstract][Full Text] [Related]
15. Elevated intrinsic cancer stem cell population in human papillomavirus-associated head and neck squamous cell carcinoma.
Zhang M; Kumar B; Piao L; Xie X; Schmitt A; Arradaza N; Cippola M; Old M; Agrawal A; Ozer E; Schuller DE; Teknos TN; Pan Q
Cancer; 2014 Apr; 120(7):992-1001. PubMed ID: 24382806
[TBL] [Abstract][Full Text] [Related]
16. Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy.
Pogorzelski M; Ting S; Gauler TC; Breitenbuecher F; Vossebein I; Hoffarth S; Markowetz J; Lang S; Bergmann C; Brandau S; Jawad JA; Schmid KW; Schuler M; Kasper S
Cell Death Dis; 2014 Feb; 5(2):e1091. PubMed ID: 24577089
[TBL] [Abstract][Full Text] [Related]
17. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
18. Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
Li C; Johnson DE
Cell Cycle; 2013 Mar; 12(6):923-34. PubMed ID: 23421999
[TBL] [Abstract][Full Text] [Related]
19. Rapalogs induce non-apoptotic, autophagy-dependent cell death in HPV-negative TP53 mutant head and neck squamous cell carcinoma.
Alam MM; Marin Fermin J; Spiller PT; Burnett C; Rong X; Moore-Medlin T; Maxwell CO; Khandelwal AR; Nathan CO
Mol Carcinog; 2022 Jan; 61(1):33-44. PubMed ID: 34598317
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
Ferris RL; Spanos WC; Leidner R; Gonçalves A; Martens UM; Kyi C; Sharfman W; Chung CH; Devriese LA; Gauthier H; Chiosea SI; Vujanovic L; Taube JM; Stein JE; Li J; Li B; Chen T; Barrows A; Topalian SL
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
